Budapest, Hungary

Gabor Zolyomi


Average Co-Inventor Count = 13.4

ph-index = 4

Forward Citations = 40(Granted Patents)


Company Filing History:


Years Active: 1986-2000

Loading Chart...
8 patents (USPTO):Explore Patents

Title: Gabor Zolyomi: Innovator in Benzodiazepine Derivatives

Introduction

Gabor Zolyomi is a notable inventor based in Budapest, Hungary. He has made significant contributions to the field of pharmaceuticals, particularly in the development of benzodiazepine derivatives. With a total of 8 patents to his name, Zolyomi's work has had a considerable impact on therapeutic applications.

Latest Patents

Zolyomi's latest patents include innovative compounds such as 1-[2-(substituted vinyl)]-3,4-dihydro-5H-2,3-benzodiazepine derivatives. This invention relates to new derivatives that affect the central nervous system and can be utilized in therapy. The compounds are characterized by a specific general formula, which defines their unique properties. Another significant patent involves 1-[2-(substituted vinyl)]-5H-2,3-benzodiazepine derivatives, which also possess central nervous activities and are aimed at treating various diseases.

Career Highlights

Throughout his career, Zolyomi has worked with prominent companies in the pharmaceutical industry, including Egis Gyógyszergyár and Egis Gyógyszergyár Rt. His experience in these organizations has allowed him to refine his expertise in drug development and innovation.

Collaborations

Zolyomi has collaborated with notable colleagues such as Tamas Hamori and Ferenc Andrasi. These partnerships have contributed to the advancement of his research and the successful development of his patented inventions.

Conclusion

Gabor Zolyomi's contributions to the field of pharmaceuticals, particularly through his innovative benzodiazepine derivatives, highlight his role as a significant inventor. His work continues to influence therapeutic practices and showcases the importance of innovation in medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…